The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

TARA >
School of Medicine >
Clinical Medicine >
Clinical Medicine (Scholarly Publications) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2262/56264

Title: Receptor tyrosine kinases and their activation in melanoma.
Author: O'BYRNE, KEN
O'DONNELL, DEARBHAILE MAIRI
GRAY, STEVEN
Author's Homepage: http://people.tcd.ie/grayst
http://people.tcd.ie/obyrneke
http://people.tcd.ie/odonnedm
Keywords: Oncology
melanoma
Receptor tyrosine kinases (RTKs)
Issue Date: 2011
Publisher: Wiley
Citation: Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC, Receptor tyrosine kinases and their activation in melanoma., Pigment Cell & Melanoma Research, 24, 3, 2011, 446 461
Series/Report no.: Pigment Cell & Melanoma Research;
24;
3;
Abstract: Receptor tyrosine kinases (RTKs) and their downstream signalling pathways have long been hypothesized to play key roles in melanoma development. A decade ago, evidence was derived largely from animal models, RTK expression studies and detection of activated RAS isoforms in a small fraction of melanomas. Predictions that overexpression of specific RTKs implied increased kinase activity and that some RTKs would show activating mutations in melanoma were largely untested. However, technological advances including rapid gene sequencing, siRNA methods and phospho-RTK arrays now give a more complete picture. Mutated forms of RTK genes including KIT, ERBB4, the EPH and FGFR families and others are known in melanoma. Additional over- or underexpressed RTKs and also protein tyrosine phosphatases (PTPs) have been reported, and activities measured. Complex interactions between RTKs and PTPs are implicated in the abnormal signalling driving aberrant growth and survival in malignant melanocytes, and indeed in normal melanocytic signalling including the response to ultraviolet radiation. Kinases are considered druggable targets, so characterisation of global RTK activity in melanoma should assist the rational development of tyrosine kinase inhibitors for clinical use.
Description: PUBLISHED
URI: http://hdl.handle.net/2262/56264
Related links: http://dx.doi.org/10.1111/j.1755-148X.2011.00836.x
Appears in Collections:Clinical Medicine (Scholarly Publications)

Files in This Item:

File Description SizeFormat
j.1755-148X.2011.00836.x.pdfPublished (author's copy) - Peer Reviewed301.04 kBAdobe PDFView/Open


This item is protected by original copyright


Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback